Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Fall;11(Suppl 1):S19-25.

Medical management of lower urinary tract symptoms

Eric E Laborde  1 , Kevin T McVary
Affiliations

Medical management of lower urinary tract symptoms

Eric E Laborde et al. Rev Urol. 2009 Fall.

Abstract

Lower urinary tract symptoms (LUTS) are a common complaint among aging men and are often caused by benign prostatic hyperplasia (BPH). A number of medical treatments for LUTS/BPH exist, such as alpha-blockers, 5alpha-reductase inhibitors, anticholinergics, phosphodiesterase type 5 (PDE5) inhibitors, and combination therapies. Agonist binding of the alpha(1A)-adrenergic receptor (AR), causing prostatic smooth muscle contraction, has been attributed to cause some LUTS. Therefore, medical therapy has aimed to block the alpha(1A)-AR and improve LUTS. Determining which therapy to choose must take into account individual patient factors as well as cost and patient choice.

Keywords: 5α-reductase inhibitors; Anticholinergics; Benign prostatic hyperplasia; Combination therapy; Lower urinary tract symptoms; Phosphodiesterase type 5 inhibitors; α-Blockers.

PubMed Disclaimer

Figures

Figure 1
Figure 1
α and β adrenergic receptor (AR) subdivisions.
See this image and copyright information in PMC

References

    1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474–479. - PubMed
    1. Price DT, Lefkowitz RJ, Caron MG, et al. Localization of mRNA for three distinct alpha 1-adrenergic receptor subtypes in human tissues: implications for human alpha-adrenergic physiology. Mol Pharmacol. 1994;45:171–175. - PubMed
    1. Malloy BJ, Price DT, Price RR, et al. Alpha1-adrenergic receptor subtypes in human detrusor. J Urol. 1998;160:937–943. - PubMed
    1. Lepor H, Tang R, Shapiro E. The alphaadrenoceptor subtype mediating the tension of human prostatic smooth muscle. Prostate. 1993;22:301–307. - PubMed
    1. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387–2398. - PubMed

LinkOut - more resources